Navigation Links
Delcath Systems Announces Completion of Public Offering
Date:11/18/2009

NEW YORK, Nov. 18 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today the closing of its public offering of 9,775,000 shares of common stock priced to the public at $3.60 per share. The offering includes 1,275,000 shares sold upon exercise by the underwriters of their over-allotment option to purchase the additional shares. All of the shares in the offering were sold by Delcath Systems. Total net proceeds to the Company were $32.4 million.

Delcath Systems plans to use the proceeds from the offering for general corporate purposes including regulatory approvals, commercialization of its products, clinical trials, capital expenditures and working capital. With the completion of this offering, Delcath Systems now has a total of 36,194,997 shares of common stock outstanding.

Cowen and Company, LLC acted as the sole book-running manager on the offering. Canaccord Adams, Wedbush PacGrow Life Sciences and Craig-Hallum Capital Group acted as co-managers.

About Delcath Systems, Inc.

Delcath Systems, Inc. is developing an innovative drug delivery device designed to treat cancers of the liver. Delcath's drug delivery system provides regional therapy by isolating the circulatory system of the liver in order to directly deliver high doses of therapeutic agents, while controlling the systemic exposure of those agents.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Delcath Systems, Inc. Prices $30.6 Million Stock Offering
2. Delcath Systems, Inc. Completes Phase III Study Enrollment
3. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
4. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
5. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
6. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
7. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
8. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
9. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
11. Varian Medical Systems to Showcase the Latest X-Ray Image Detectors and X-Ray Tubes at the MEDICA 2009 International Trade Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... available for sale, The Armor1 Ankle Roll Guard is a ... by cushioning the ankle from an inversion or "roll." ... of any shoe type and allows the user to ... against sprains. With customers in physical therapy, podiatry, and ...
(Date:1/23/2015)... Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number of ... compound, LB‑100, is being conducted, has been expanded from 1 ... M.D., the founder and President of Lixte, said that, "the ... site. Accrual of patients, however, was slower than projected. The ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
Breaking Medicine Technology:The Armor1 Ankle Roll Guard is the New Breakthrough Solution for Ankle Sprain Prevention! 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Reportlinker.com announces that a new market ... , The Global Drug Delivery Market: ... http://www.reportlinker.com/p0158356/The-Global-Drug-Delivery-Market-Research-Trends-and-Market-Outlook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... in recent years become a key partner ...
... YORK, Nov. 10 Reportlinker.com announces that ... in its catalogue. , Blood ... http://www.reportlinker.com/p0161818/Blood-and-Lymphatic-System-Hyperlipemia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... contains detailed information on the current drug ...
Cached Medicine Technology:Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 2Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 3Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 4Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 5Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 6Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 7Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 8Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 9Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 10Reportlinker Adds The Global Drug Delivery Market: Research Trends and Market Outlook 11Reportlinker Adds Blood and Lymphatic System Hyperlipemia 2Reportlinker Adds Blood and Lymphatic System Hyperlipemia 3
(Date:1/23/2015)... Hastings and Hastings, a law firm in ... number of legal representation client review requests for slip and ... steady rise in the number of slip and fall related ... the Valley. With that said, a large number of injury ... experienced law firm. Hastings and Hastings is a personal injury ...
(Date:1/22/2015)... Liberty University has received accreditation for its resident ... Council for Accreditation of Counseling & Related Educational Programs ... for Counseling & Family Studies , is under the leadership ... School of Behavioral Sciences. Prior to the formation of the ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... ... Auction Ends May 23rd , ... Angeles, CA (Vocus) May 21, 2010 -- Jay Manuel has opened up his private ... Cause. These are not just breathtakingly stunning, many are one-of-a-kind items right off the runways. ...
... ... weapon – against wrinkles -- up its sleeve. Make sure you tune in as we ... , ... 2010 -- The Balancing Act just might have a secret weapon – against wrinkles -- up ...
... ... lawsuit can use the potential lawsuit settlement as collateral to get a non-recourse settlement loan. ... (PRWEB) May 21, 2010 ... loan on most types of pending employment discrimination and wrongful termination lawsuits., , , Lawsuit ...
... ... won’t have that many candles on it, but Ross & Yerger is indeed celebrating 150 ... ... cake probably won’t have that many candles on it, but Ross & Yerger is indeed ...
... with certain variants who were treated with low-dose cancer ... 20 (HealthDay News) -- A new study finds that ... more likely than other survivors to develop heart disease. ... personalize treatment for certain children with cancer to prevent ...
... drugs outweigh these risks, experts say , THURSDAY, ... drugs called statins may be at heightened risk ... British researchers report. , Statins, which include the ... recommended for patients with high cholesterol. Studies have ...
Cached Medicine News:Health News:Jay Manuel's Legendary Red Carpet Fashion Styles Continue to be a Huge Hit with Fans 2Health News:Jay Manuel's Legendary Red Carpet Fashion Styles Continue to be a Huge Hit with Fans 3Health News:O2 Media's Hit Morning TV Show ‘The Balancing Act' Welcomes Absolute Miracle Cream to the Program 2Health News:Easy Lawsuit Funding Now Offers Lawsuit Loan on All Types of Employment Lawsuits 2Health News:Easy Lawsuit Funding Now Offers Lawsuit Loan on All Types of Employment Lawsuits 3Health News:Easy Lawsuit Funding Now Offers Lawsuit Loan on All Types of Employment Lawsuits 4Health News:Ross & Yerger Celebrates 150 Years As A Risk-Management Company, And A Proud Part Of The Community 2Health News:Heart Disease Among Childhood Cancer Survivors Tied to Gene Mutations 2Health News:Statin Use Tied to Eye, Kidney, Liver Troubles 2Health News:Statin Use Tied to Eye, Kidney, Liver Troubles 3Health News:Statin Use Tied to Eye, Kidney, Liver Troubles 4
1mm by 7mm horizontal punch. Flat serrated handle. Overall length 87mm....
... Central platform with integrated neck. ... platform utilizing an internal spring to ... use. Cutting Block fits into precision ... trephine blades sized 6.25 - 9.0mm. ...
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... German Craftsmanship have produced ... in the world. Ocutek® ... to you! Only holders ... certificate, which requires and ...
Medicine Products: